Objectives: A double blind randomized placebo-controlled clinical trial was designed and carried out to validate the hypothesis that the use of lozenges containing Lactobacillus brevis CD2 (VSL Pharmaceuticals, Inc.) may reduce plaque-pH, salivary mutans streptococci and bleeding on probing in a sample of high caries risk schoolchildren. The investigation had an experimental period of 8 weeks with two arms, Lb brevis CD2 lozenges and no-Lb brevis lozenges. Methods: 191 children (aged 6-8 yy), presenting more than one carious lesion and salivary sm concentration ≥105 CFU/ml were examined at baseline (t0), after three weeks (t1), after six weeks of lozenges use (t2) and two weeks after the end of lozenges use (t3). Plaque-pH was assessed using the strip method following a sucrose challenge. Area under the curve (AUC5.7 and AUC6.2) was recorded. Salivary mutans streptococci (ms CFU/mL) was counted. Results: Bleeding score at t0 was similar in the two groups, while at t2 and t3 a statistically significantly lower value was registered in LB-brevis CD2 group (p=0.02 and p=0.03, respectively). At t0, plaque-pH and salivary ms concentration values in both groups were similar (p =0.18 and p=0.48, respectively). Mean areas (AUC5.7 and AUC6.2) were statistically significantly lower in the test group at t1, t2 and t3. Subjects from the test group showed a statistically significant decrease (p=0.01) in salivary ms concentration (5.4 at t0, 4.9 at t2). AUC at t2 was statistically significant smaller in children from test group (p=0.01 AUC5.7 and p=0.03 AUC6.2) in relation to salivary ms concentration in comparison to children from control group, both for children with ms concentration ≥105 and with a concentration <105. Conclusions: Six weeks use of lozenges containing Lactobacillus brevis CD2 showed beneficial effects on oral health, including a reduction of salivary mutans streptococci, plaque acidogenicity and bleeding on probing. (Trial Registration Number NCT01601145 08/21/2012)
Effect of Lactobacillus brevis CD2 lozenges in High Risk Schoolchildren / Campus, Guglielmo Giuseppe; Cocco, Fabio; Carta, Giovanna; Cagetti, Mariagrazia; Strohmenger, Laura; Lingström, Peter. - (2013). (Intervento presentato al convegno IADR/AADR/CADR General Session & Exhibition (March 20-23, 2013) (Seattle, Washington)).
Effect of Lactobacillus brevis CD2 lozenges in High Risk Schoolchildren
CAMPUS, Guglielmo Giuseppe;COCCO, Fabio;STROHMENGER, Laura;
2013-01-01
Abstract
Objectives: A double blind randomized placebo-controlled clinical trial was designed and carried out to validate the hypothesis that the use of lozenges containing Lactobacillus brevis CD2 (VSL Pharmaceuticals, Inc.) may reduce plaque-pH, salivary mutans streptococci and bleeding on probing in a sample of high caries risk schoolchildren. The investigation had an experimental period of 8 weeks with two arms, Lb brevis CD2 lozenges and no-Lb brevis lozenges. Methods: 191 children (aged 6-8 yy), presenting more than one carious lesion and salivary sm concentration ≥105 CFU/ml were examined at baseline (t0), after three weeks (t1), after six weeks of lozenges use (t2) and two weeks after the end of lozenges use (t3). Plaque-pH was assessed using the strip method following a sucrose challenge. Area under the curve (AUC5.7 and AUC6.2) was recorded. Salivary mutans streptococci (ms CFU/mL) was counted. Results: Bleeding score at t0 was similar in the two groups, while at t2 and t3 a statistically significantly lower value was registered in LB-brevis CD2 group (p=0.02 and p=0.03, respectively). At t0, plaque-pH and salivary ms concentration values in both groups were similar (p =0.18 and p=0.48, respectively). Mean areas (AUC5.7 and AUC6.2) were statistically significantly lower in the test group at t1, t2 and t3. Subjects from the test group showed a statistically significant decrease (p=0.01) in salivary ms concentration (5.4 at t0, 4.9 at t2). AUC at t2 was statistically significant smaller in children from test group (p=0.01 AUC5.7 and p=0.03 AUC6.2) in relation to salivary ms concentration in comparison to children from control group, both for children with ms concentration ≥105 and with a concentration <105. Conclusions: Six weeks use of lozenges containing Lactobacillus brevis CD2 showed beneficial effects on oral health, including a reduction of salivary mutans streptococci, plaque acidogenicity and bleeding on probing. (Trial Registration Number NCT01601145 08/21/2012)I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
